Phosphodiesterase-5 Inhibitors and Vacuum Erection Device for Penile Rehabilitation After Laparoscopic Nerve-Preserving Radical Proctectomy for Rectal Cancer: A Prospective Controlled Trial
The current study sought to clarify the role of phosphodiesterase type 5 inhibitors (PDE-5i) and a vacuum erection device (VED) in penile rehabilitation after laparoscopic nerve-preserving radical proctectomy (LNRP) for rectal cancer. Participants were assigned to one of the following arms—no-interv...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2017-05-01
|
Series: | American Journal of Men's Health |
Online Access: | https://doi.org/10.1177/1557988316665084 |
id |
doaj-3117621aa2554157828ef8e16cd208bc |
---|---|
record_format |
Article |
spelling |
doaj-3117621aa2554157828ef8e16cd208bc2020-11-25T03:03:15ZengSAGE PublishingAmerican Journal of Men's Health1557-98831557-98912017-05-011110.1177/1557988316665084Phosphodiesterase-5 Inhibitors and Vacuum Erection Device for Penile Rehabilitation After Laparoscopic Nerve-Preserving Radical Proctectomy for Rectal Cancer: A Prospective Controlled TrialHaijun Deng MD, PhD0Dong Liu MBBS1Xiangming Mao MD, PhD2Xiaoliang Lan MD3Hao Liu MD, PhD4Guoxin Li MD, PhD5NanFang Hospital, Southern Medical University, Guangzhou, ChinaNanFang Hospital, Southern Medical University, Guangzhou, ChinaPeking University Shenzhen Hospital, Shenzhen, ChinaNanFang Hospital, Southern Medical University, Guangzhou, ChinaNanFang Hospital, Southern Medical University, Guangzhou, ChinaNanFang Hospital, Southern Medical University, Guangzhou, ChinaThe current study sought to clarify the role of phosphodiesterase type 5 inhibitors (PDE-5i) and a vacuum erection device (VED) in penile rehabilitation after laparoscopic nerve-preserving radical proctectomy (LNRP) for rectal cancer. Participants were assigned to one of the following arms—no-intervention, nightly use of sildenafil 25 mg for 3 months after surgery, or concurrent use of nightly sildenafil 25 mg/day for 3 months and a vacuum erection device (VED) 10 to 15 minutes/day for 3 months—in a nonrandomized fashion. All participants had a follow-up of over 12 months prospectively, and patients had baseline, 3-, 6-, and 12-month assessment based on the International Index of Erectile Function–5 (IIEF-5). Seventy-one cases were included in final analyses. In the no-intervention group, the mean baseline IIEF-5 score of 21.9 decreased rapidly to 5.0 at 3 months ( p < .001), 9.2 at 6 months ( p < .001), and stayed at 10.9 at 12 months ( p < .001). In the single therapy group, the mean baseline IIEF-5 score of 22.4 decreased dramatically to 9.0 at 3 months ( p < .001), 14.9 at 6 months ( p = .005), and stayed at 15.1 at 12 months ( p = .005). In the combined therapy group, the mean baseline IIEF-5 score of 23.0 decreased slightly to 15.0 at 3 months ( p = .005), 18.0 at 6 months ( p = .038), and maintained at 18.7 at 12 months ( p = .163). Findings suggested an over 50% decline in the quality of erection function of the patients after LNRP. The early use of PDE-5i alone or combined use of PDE-5i and VED after LNRP maintained erectile function at 12 months.https://doi.org/10.1177/1557988316665084 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Haijun Deng MD, PhD Dong Liu MBBS Xiangming Mao MD, PhD Xiaoliang Lan MD Hao Liu MD, PhD Guoxin Li MD, PhD |
spellingShingle |
Haijun Deng MD, PhD Dong Liu MBBS Xiangming Mao MD, PhD Xiaoliang Lan MD Hao Liu MD, PhD Guoxin Li MD, PhD Phosphodiesterase-5 Inhibitors and Vacuum Erection Device for Penile Rehabilitation After Laparoscopic Nerve-Preserving Radical Proctectomy for Rectal Cancer: A Prospective Controlled Trial American Journal of Men's Health |
author_facet |
Haijun Deng MD, PhD Dong Liu MBBS Xiangming Mao MD, PhD Xiaoliang Lan MD Hao Liu MD, PhD Guoxin Li MD, PhD |
author_sort |
Haijun Deng MD, PhD |
title |
Phosphodiesterase-5 Inhibitors and Vacuum Erection Device for Penile Rehabilitation After Laparoscopic Nerve-Preserving Radical Proctectomy for Rectal Cancer: A Prospective Controlled Trial |
title_short |
Phosphodiesterase-5 Inhibitors and Vacuum Erection Device for Penile Rehabilitation After Laparoscopic Nerve-Preserving Radical Proctectomy for Rectal Cancer: A Prospective Controlled Trial |
title_full |
Phosphodiesterase-5 Inhibitors and Vacuum Erection Device for Penile Rehabilitation After Laparoscopic Nerve-Preserving Radical Proctectomy for Rectal Cancer: A Prospective Controlled Trial |
title_fullStr |
Phosphodiesterase-5 Inhibitors and Vacuum Erection Device for Penile Rehabilitation After Laparoscopic Nerve-Preserving Radical Proctectomy for Rectal Cancer: A Prospective Controlled Trial |
title_full_unstemmed |
Phosphodiesterase-5 Inhibitors and Vacuum Erection Device for Penile Rehabilitation After Laparoscopic Nerve-Preserving Radical Proctectomy for Rectal Cancer: A Prospective Controlled Trial |
title_sort |
phosphodiesterase-5 inhibitors and vacuum erection device for penile rehabilitation after laparoscopic nerve-preserving radical proctectomy for rectal cancer: a prospective controlled trial |
publisher |
SAGE Publishing |
series |
American Journal of Men's Health |
issn |
1557-9883 1557-9891 |
publishDate |
2017-05-01 |
description |
The current study sought to clarify the role of phosphodiesterase type 5 inhibitors (PDE-5i) and a vacuum erection device (VED) in penile rehabilitation after laparoscopic nerve-preserving radical proctectomy (LNRP) for rectal cancer. Participants were assigned to one of the following arms—no-intervention, nightly use of sildenafil 25 mg for 3 months after surgery, or concurrent use of nightly sildenafil 25 mg/day for 3 months and a vacuum erection device (VED) 10 to 15 minutes/day for 3 months—in a nonrandomized fashion. All participants had a follow-up of over 12 months prospectively, and patients had baseline, 3-, 6-, and 12-month assessment based on the International Index of Erectile Function–5 (IIEF-5). Seventy-one cases were included in final analyses. In the no-intervention group, the mean baseline IIEF-5 score of 21.9 decreased rapidly to 5.0 at 3 months ( p < .001), 9.2 at 6 months ( p < .001), and stayed at 10.9 at 12 months ( p < .001). In the single therapy group, the mean baseline IIEF-5 score of 22.4 decreased dramatically to 9.0 at 3 months ( p < .001), 14.9 at 6 months ( p = .005), and stayed at 15.1 at 12 months ( p = .005). In the combined therapy group, the mean baseline IIEF-5 score of 23.0 decreased slightly to 15.0 at 3 months ( p = .005), 18.0 at 6 months ( p = .038), and maintained at 18.7 at 12 months ( p = .163). Findings suggested an over 50% decline in the quality of erection function of the patients after LNRP. The early use of PDE-5i alone or combined use of PDE-5i and VED after LNRP maintained erectile function at 12 months. |
url |
https://doi.org/10.1177/1557988316665084 |
work_keys_str_mv |
AT haijundengmdphd phosphodiesterase5inhibitorsandvacuumerectiondeviceforpenilerehabilitationafterlaparoscopicnervepreservingradicalproctectomyforrectalcanceraprospectivecontrolledtrial AT dongliumbbs phosphodiesterase5inhibitorsandvacuumerectiondeviceforpenilerehabilitationafterlaparoscopicnervepreservingradicalproctectomyforrectalcanceraprospectivecontrolledtrial AT xiangmingmaomdphd phosphodiesterase5inhibitorsandvacuumerectiondeviceforpenilerehabilitationafterlaparoscopicnervepreservingradicalproctectomyforrectalcanceraprospectivecontrolledtrial AT xiaolianglanmd phosphodiesterase5inhibitorsandvacuumerectiondeviceforpenilerehabilitationafterlaparoscopicnervepreservingradicalproctectomyforrectalcanceraprospectivecontrolledtrial AT haoliumdphd phosphodiesterase5inhibitorsandvacuumerectiondeviceforpenilerehabilitationafterlaparoscopicnervepreservingradicalproctectomyforrectalcanceraprospectivecontrolledtrial AT guoxinlimdphd phosphodiesterase5inhibitorsandvacuumerectiondeviceforpenilerehabilitationafterlaparoscopicnervepreservingradicalproctectomyforrectalcanceraprospectivecontrolledtrial |
_version_ |
1724686776713347072 |